Halozyme Therapeutics, Inc. (HALO)
67.30
-0.40
(-0.59%)
USD |
NASDAQ |
Dec 31, 16:00
67.17
-0.13
(-0.19%)
After-Hours: 20:00
Halozyme Therapeutics Free Cash Flow: 602.40M for Sept. 30, 2025
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Johnson & Johnson | 20.46B |
| Merck & Co., Inc. | 13.05B |
| AIM ImmunoTech, Inc. | -13.33M |
| Bristol Myers Squibb Co. | 15.30B |
| Protalix Biotherapeutics, Inc. | -11.69M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 178.60M |
| Cash from Investing (Quarterly) | 201.61M |
| Cash from Financing (Quarterly) | -22.40M |
| Free Cash Flow Per Share (Quarterly) | 1.435 |
| Free Cash Flow to Equity (Quarterly) | 173.91M |
| Free Cash Flow to Firm (Quarterly) | 179.00M |
| Free Cash Flow Yield | 7.13% |